questionText: To ask the Secretary of State for Health and Social Care, whether he has made an assessment of (a) the potential impact of the level of the Voluntary Scheme for Branded Medicines Pricing and Access payment percentages on and (b) other factors affecting the decisions by pharmaceutical companies on whether to invest in the UK.
answerText: The Government has considered in broad terms the link between volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which ope...
heading: Voluntary Scheme for Branded Medicines Pricing and Access